Ping-Chen Hou, Wilson Aala, Wei-Ting Tu, John A McGrath, Chao-Kai Hsu
{"title":"Real-world experience of using dupilumab and JAK inhibitors to manage pruritus in epidermolysis bullosa pruriginosa.","authors":"Ping-Chen Hou, Wilson Aala, Wei-Ting Tu, John A McGrath, Chao-Kai Hsu","doi":"10.1002/ski2.445","DOIUrl":null,"url":null,"abstract":"<p><p>Epidermolysis bullosa pruriginosa (EBP) is a form of dystrophic EB associated with severe pruritus and has skewed Th2 inflammation. Our study suggests that JAK inhibitors may offer superior efficacy compared to dupilumab in treating EBP. Moreover, JAK inhibitors downregulate JAK-STAT signalling and Th1/2 cell differentiation in lesional skin while not in peripheral blood.</p>","PeriodicalId":74804,"journal":{"name":"Skin health and disease","volume":"4 5","pages":"e445"},"PeriodicalIF":0.0000,"publicationDate":"2024-08-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11442062/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Skin health and disease","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1002/ski2.445","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/10/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0
Abstract
Epidermolysis bullosa pruriginosa (EBP) is a form of dystrophic EB associated with severe pruritus and has skewed Th2 inflammation. Our study suggests that JAK inhibitors may offer superior efficacy compared to dupilumab in treating EBP. Moreover, JAK inhibitors downregulate JAK-STAT signalling and Th1/2 cell differentiation in lesional skin while not in peripheral blood.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
